237 related articles for article (PubMed ID: 34670399)
1. Targeting the tumor microenvironment of Ewing sarcoma.
Morales E; Olson M; Iglesias F; Luetkens T; Atanackovic D
Immunotherapy; 2021 Dec; 13(17):1439-1451. PubMed ID: 34670399
[TBL] [Abstract][Full Text] [Related]
2. Cellular immunotherapy strategies for Ewing sarcoma.
Rossig C
Immunotherapy; 2014; 6(5):611-21. PubMed ID: 24896629
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation.
Henrich IC; Jain K; Young R; Quick L; Lindsay JM; Park DH; Oliveira AM; Blobel GA; Chou MM
Cancer Res; 2021 Apr; 81(8):2171-2183. PubMed ID: 33558334
[TBL] [Abstract][Full Text] [Related]
4. New strategies in ewing sarcoma: lost in translation?
Arnaldez FI; Helman LJ
Clin Cancer Res; 2014 Jun; 20(12):3050-6. PubMed ID: 24756371
[TBL] [Abstract][Full Text] [Related]
5. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
6. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
Front Immunol; 2021; 12():791206. PubMed ID: 34804076
[TBL] [Abstract][Full Text] [Related]
7. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging.
Liebsch L; Kailayangiri S; Beck L; Altvater B; Koch R; Dierkes C; Hotfilder M; Nagelmann N; Faber C; Kooijman H; Ring J; Vieth V; Rossig C
Br J Cancer; 2013 Aug; 109(3):658-66. PubMed ID: 23839490
[TBL] [Abstract][Full Text] [Related]
8. Potential approaches to the treatment of Ewing's sarcoma.
Yu H; Ge Y; Guo L; Huang L
Oncotarget; 2017 Jan; 8(3):5523-5539. PubMed ID: 27740934
[TBL] [Abstract][Full Text] [Related]
9. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
10. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.
Kailayangiri S; Altvater B; Meltzer J; Pscherer S; Luecke A; Dierkes C; Titze U; Leuchte K; Landmeier S; Hotfilder M; Dirksen U; Hardes J; Gosheger G; Juergens H; Rossig C
Br J Cancer; 2012 Mar; 106(6):1123-33. PubMed ID: 22374462
[TBL] [Abstract][Full Text] [Related]
11. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
[TBL] [Abstract][Full Text] [Related]
12. Role of immunotherapy in Ewing sarcoma.
Morales E; Olson M; Iglesias F; Dahiya S; Luetkens T; Atanackovic D
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33293354
[TBL] [Abstract][Full Text] [Related]
13. Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy.
Sand LG; Berghuis D; Szuhai K; Hogendoorn PC
Cancer Immunol Immunother; 2016 Aug; 65(8):995-1002. PubMed ID: 27369431
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine-2,3-dioxygenase in an immunotherapy model for Ewing sarcoma.
Max D; Kühnöl CD; Burdach S; Niu L; Staege MS; Föll JL
Anticancer Res; 2014 Nov; 34(11):6431-41. PubMed ID: 25368243
[TBL] [Abstract][Full Text] [Related]
15. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.
Englisch A; Altvater B; Kailayangiri S; Hartmann W; Rossig C
Pediatr Blood Cancer; 2020 Oct; 67(10):e28313. PubMed ID: 32729251
[TBL] [Abstract][Full Text] [Related]
16. A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease.
Brinkrolf P; Landmeier S; Altvater B; Chen C; Pscherer S; Rosemann A; Ranft A; Dirksen U; Juergens H; Rossig C
Int J Cancer; 2009 Aug; 125(4):879-86. PubMed ID: 19480009
[TBL] [Abstract][Full Text] [Related]
17. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma.
Luo W; Hoang H; Liao Y; Pan J; Ayello J; Cairo MS
Front Immunol; 2023; 14():1277987. PubMed ID: 37868989
[TBL] [Abstract][Full Text] [Related]
18. SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS.
Cohen IJ; Toledano H; Stein J; Kollender Y; Fenig E; Konen O; Bar-Sever Z; Issakov J; Feinmesser M; Avigad S; Ash S
Cancer Chemother Pharmacol; 2019 May; 83(5):859-866. PubMed ID: 30770960
[TBL] [Abstract][Full Text] [Related]
19. Nonmetastatic pelvic Ewing sarcoma: report of the French society of pediatric oncology.
Carrie C; Mascard E; Gomez F; Habrand JL; Alapetite C; Oberlin O; Moncho V; Hoffstetter S
Med Pediatr Oncol; 1999 Nov; 33(5):444-9. PubMed ID: 10531567
[TBL] [Abstract][Full Text] [Related]
20. Current status of immunotherapy for sarcomas.
Miwa S; Nishida H; Tsuchiya H
Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
